TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33736670

Group type: EXPERIMENTAL
Intervention: Implementation group 1 - received an evidence-based policy recommendation document guiding weekend allied health resource allocation decisions
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Implementation group 2 - received the same policy recommendation document with support from a knowledge broker
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 34483325

Group type: EXPERIMENTAL
Intervention: Cancellous screws (CSs)
Number of subjects: 819

Group type: COMPARATOR
Intervention: Sliding hip screws
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Trauma‐fellowship‐trained surgeons
Number of subjects: 819

Group type: COMPARATOR
Intervention: Non‐trauma‐fellowship‐trained surgeons
Number of subjects: 819
Study: 34770157

Group type: EXPERIMENTAL
Intervention: Continuous Energy Restriction (CER)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction (IER)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (CERG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (between groups)
Number of subjects: 26
Study: 32034849

Group type: EXPERIMENTAL
Intervention: Self-help materials with usual care (n=336)
Number of subjects: 678

Group type: COMPARATOR
Intervention: Usual care alone (n=342)
Number of subjects: 678
Study: 35761123

Group type: EXPERIMENTAL
Intervention: P-FOLFIRI (arm A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: FOLFIRI alone (arm B)
Number of subjects: 31
Study: 33449503

Group type: EXPERIMENTAL
Intervention: Conditioned open-label placebo (COLP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 0
Study: 34459996

Group type: EXPERIMENTAL
Intervention: Cocoyam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plantain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (WHO recommended limits)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily Intake of Metals (DIM) and Target Hazard Quotient (THQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifetime probability of contracting cancer
Number of subjects: 0
Study: 36459338

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) group, hemodynamic management guided with clinical parameters and bedside US findings
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group, hemodynamic management based solely on clinical parameters
Number of subjects: 111
Study: 34193504

Group type: EXPERIMENTAL
Intervention: Bromocriptine (10 mg/day and 22.5 mg/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 6
Study: 32957356

Group type: EXPERIMENTAL
Intervention: Nursing intervention based on motivational interview
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (informative session only)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (control and experimental)
Number of subjects: 60
Study: 35451858

Group type: EXPERIMENTAL
Intervention: galcanezumab 120 mg/month (following a 240 mg loading dose)
Number of subjects: 462

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: galcanezumab
Number of subjects: 462
Study: 34614118

Group type: EXPERIMENTAL
Intervention: At-home bleaching (10% carbamide peroxide)
Number of subjects: 130

Group type: COMPARATOR
Intervention: In-office bleaching (35% hydrogen peroxide)
Number of subjects: 130
Study: 32541837

Group type: EXPERIMENTAL
Intervention: Perturbation warning (only warned of a perturbation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Perturbation exposure (exposed to fifty unilateral slip-like perturbations)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Perturbation removal (kept unaware of perturbation removal)
Number of subjects: 30
Study: 35764992

Group type: EXPERIMENTAL
Intervention: Healthy food nudges and pricing strategies
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group receiving no intervention
Number of subjects: 360
Study: 33318119

Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen therapy using a portable oxygen concentrator (POC) during daily activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambulatory air using an identical POC modified to deliver air
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambulatory air
Number of subjects: 0
Study: 35589170

Group type: COMPARATOR
Intervention: Circumferential pulmonary vein isolation (CPVI) alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Additional electrical posterior box isolation (POBI)
Number of subjects: 150
Study: 34089147

Group type: EXPERIMENTAL
Intervention: AS MDI (90 μg/inhalation, cumulative doses up to 1440 μg)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: AS MDI (90 μg and 180 μg)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Proventil (90 μg and 180 μg)
Number of subjects: 132
Study: 35870076

Group type: COMPARATOR
Intervention: Control app (ultraviolet index only)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sun4Health® app (personalised recommendations and sun overexposure alerts)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sun4Health®-3D app (personalised recommendations connected to a wearable device)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control app
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sun4Health® app
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sun4Health®-3D app
Number of subjects: 59
Study: 33938254

Group type: EXPERIMENTAL
Intervention: Nursing records analyzed using document vector analysis for predicting aspiration pneumonia onset.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nursing records for the patient group with aspiration pneumonia.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nursing records for the non-onset control group.
Number of subjects: 0
Study: 33231638

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2796

Group type: COMPARATOR
Intervention: Control group (diabetes support and education)
Number of subjects: 2796
Study: 35168010

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 40
Study: 33199419

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) performed by inflating a thigh tourniquet to 300 mm Hg 4 times for 5 min, done two times: first after declaration of brain death and second before transferring to the operating theatre.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Sham intervention (tourniquet applied but not inflated).
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: RIPC intervention
Number of subjects: 500
Study: 32687695

Group type: EXPERIMENTAL
Intervention: Sitafloxacin granules 50 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitafloxacin granules 100 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitafloxacin granules 200 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitafloxacin granules 50 mg with high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitafloxacin granules 100 mg once daily for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABCB1 (rs1045642) mutation group
Number of subjects: 0

Group type: COMPARATOR
Intervention: UGT1A1 (rs2741049) mutation group
Number of subjects: 0

Group type: COMPARATOR
Intervention: UGT1A9 (rs3832043) mutation group
Number of subjects: 0
Study: 32513291

Group type: EXPERIMENTAL
Intervention: MoVo‐LISA plus MoVo‐App
Number of subjects: 224

Group type: COMPARATOR
Intervention: MoVo‐LISA alone (without the app)
Number of subjects: 224
Study: 33870728

Group type: EXPERIMENTAL
Intervention: HDL cholesterol efflux
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory capacity
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Antioxidative capacity
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: HDL cholesterol concentrations
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: HDL functionality measures
Number of subjects: 446
Study: 32701903

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/d)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 34864274

Group type: EXPERIMENTAL
Intervention: Modified long-axis in-plane ultrasound guidance (M-LAIP)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Short-axis out-of-plane (SAOP)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conventional palpation (C-P)
Number of subjects: 201
Study: 33273349

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 455

Group type: COMPARATOR
Intervention: Immediate surgery (control group)
Number of subjects: 455
Study: 35933563

Group type: EXPERIMENTAL
Intervention: PKP combined with zoledronic acid (ZOL)
Number of subjects: 238

Group type: COMPARATOR
Intervention: PKP only (control group)
Number of subjects: 238
Study: 33413631

Group type: EXPERIMENTAL
Intervention: Imaginal desensitisation plus motivational interviewing (IDMI) intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 60
Study: 36859448

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Community Programme (HLCP) - 14 seminars (twice per week), stress-regulation and cooking workshops, coaching sessions for healthy plant-based diet, stress regulation, regular exercise, social support.
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (CG) - no specific intervention details provided.
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Community Programme (HLCP) - 8-week intervention.
Number of subjects: 143
Study: 34521624

Group type: COMPARATOR
Intervention: Anastrozole (A)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Anastrozole plus fulvestrant (A+F)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: High sTK1 at baseline and subsequent time-points
Number of subjects: 432
Study: 34332429

Group type: EXPERIMENTAL
Intervention: Integrated Coping Awareness Therapy (I-CAT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 36
Study: 34419680

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 850

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study: 32828825

Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 431

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 431
Study: 33546045

Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin Pill combined with Western medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine Western medicine
Number of subjects: 0
Study: 35334923

Group type: EXPERIMENTAL
Intervention: Maternal vitamin D sufficiency
Number of subjects: 0
Study: 32961065

Group type: EXPERIMENTAL
Intervention: HIIT plus lifestyle education (HIIT+)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 41
Study: 32864760

Group type: EXPERIMENTAL
Intervention: 5% cysteamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4% hydroquinone
Number of subjects: 40
Study: 35893858

Group type: EXPERIMENTAL
Intervention: 1-MNA supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: NO-1-MNA (control group)
Number of subjects: 50
Study: 32768182

Group type: EXPERIMENTAL
Intervention: Fully guided protocol (24 implants)
Number of subjects: 12
Study: 35264114

Group type: EXPERIMENTAL
Intervention: Genetic variants based on individual single nucleotide polymorphisms (SNPs) and a 27 SNP genetic risk score (GRS) derived from SNPs strongly associated with CHD
Number of subjects: 4932

Group type: EXPERIMENTAL
Intervention: 27 SNP genetic risk score (GRS)
Number of subjects: 4932
Study: 34719269

Group type: EXPERIMENTAL
Intervention: On-demand removal (ODR) of syndesmotic screws
Number of subjects: 197

Group type: COMPARATOR
Intervention: Routine removal (RR) of syndesmotic screws
Number of subjects: 197
Study: 35787516

Group type: EXPERIMENTAL
Intervention: SM+FB (Self-Monitoring plus Feedback)
Number of subjects: 502

Group type: COMPARATOR
Intervention: SM (Self-Monitoring only)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: FB messages opened
Number of subjects: 502
Study: 32971190

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study: 32828117

Group type: EXPERIMENTAL
Intervention: Intranasal steroid (fluticasone furoate, 110 mcg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 32501868

Group type: EXPERIMENTAL
Intervention: OPRX-106 2 mg administered orally once daily for 8 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: OPRX-106 8 mg administered orally once daily for 8 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: OPRX-106 (both dosages)
Number of subjects: 25
Study: 34027992

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided phrenic nerve block (ropivacaine 0.75 mg/mL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (isotonic sodium chloride 0.9 mg/mL)
Number of subjects: 12
Study: 32546198

Group type: EXPERIMENTAL
Intervention: Systematic HRQoL assessment using the CHES software before each consultation coupled with therapeutic information (three workshops related to understanding the prescription, nutrition, and fatigue)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Systematic HRQoL assessment
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Routine HRQoL assessment
Number of subjects: 342
Study: 36042217

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop insulin delivery system
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard diabetes care
Number of subjects: 42
Study: 33831710

Group type: EXPERIMENTAL
Intervention: Expressive suppression
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cognitive reappraisal
Number of subjects: 117
Study: 34415801

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography (Doppler‐CO)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Thermodilution using pulmonary artery catheters (PAC‐CO)
Number of subjects: 141
Study: 33858855

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 26
Study: 99370165

Group type: EXPERIMENTAL
Intervention: IFN-alpha (6 MU given three times a week)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IFN plus ribavirin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Combination therapy (IFN plus ribavirin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: IFN alone
Number of subjects: 15
Study: 34120135

Group type: EXPERIMENTAL
Intervention: Head-Mounted Display (HMD) simulation
Number of subjects: 115

Group type: COMPARATOR
Intervention: In-person simulation
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both groups (HMD and in-person)
Number of subjects: 115
Study: 33181508

Group type: EXPERIMENTAL
Intervention: Hemoperfusion (HP) with CytoSorb cartridge, 2 consecutive sessions started 6-7 days after hospital admission.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (C) without HP treatment.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hemoperfusion (HP) with CytoSorb cartridge.
Number of subjects: 9
Study: 34389273

Group type: EXPERIMENTAL
Intervention: Copanlisib plus R-B (Rituximab plus Bendamustine)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Copanlisib plus R-CHOP (Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)
Number of subjects: 21
Study: 36065528

Group type: EXPERIMENTAL
Intervention: Treatment regimen (specific medications not detailed)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Continued observation
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Treatment for infertility (specific medications not detailed)
Number of subjects: 520
Study: 33995776

Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 33072497

Group type: EXPERIMENTAL
Intervention: Test results access (parent only vs. parent and clinic) and follow up approaches (yes/no)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Kit distribution by clinicians
Number of subjects: 240
Study: 35441466

Group type: EXPERIMENTAL
Intervention: Regular insulin produced by Bioton S.A. (0.3 units/kg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Humulin® R (0.3 units/kg)
Number of subjects: 56
Study: 33040565

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (40 Gy/15 fractions) with concurrent and adjuvant temozolomide (TMZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard radiotherapy (60 Gy/30 fractions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 35947375

Group type: EXPERIMENTAL
Intervention: Decision aid group (126 patients)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (109 patients)
Number of subjects: 235
Study: 32997647

Group type: EXPERIMENTAL
Intervention: Team-based learning strategy
Number of subjects: 33
Study: 35789270

Group type: EXPERIMENTAL
Intervention: trastuzumab-based therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: lapatinib-based therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: trastuzumab-lapatinib-based therapy
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: trastuzumab-based neoadjuvant therapy in NeoSphere cohort
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: whole study cohort in NeoSphere
Number of subjects: 180
Study: 34090625

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 2040

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 2040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2040
Study: 32141766

Group type: EXPERIMENTAL
Intervention: Melphalan flufenamide + dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pomalidomide + dexamethasone
Number of subjects: 0
Study: 33070223

Group type: EXPERIMENTAL
Intervention: 1 mM l-carnitine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (without l-carnitine)
Number of subjects: 38
Study: 34118388

Group type: EXPERIMENTAL
Intervention: Browsing TikTok for 20 min
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no TikTok browsing)
Number of subjects: 80
Study: 34459765

Group type: EXPERIMENTAL
Intervention: Basic therapy + inhalations with high concentrated oxygen with Camomile Oil
Number of subjects: 70

Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 70
Study: 32115879

Group type: EXPERIMENTAL
Intervention: Nasal glucagon (NG) 3 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intramuscular glucagon (IMG) 1 mg
Number of subjects: 75
Study: 34724145

Group type: EXPERIMENTAL
Intervention: Derivation set (Cox proportional hazards regression model)
Number of subjects: 2051

Group type: EXPERIMENTAL
Intervention: Validation set (Cox proportional hazards regression model)
Number of subjects: 2051

Group type: EXPERIMENTAL
Intervention: Derivation set (scoring model)
Number of subjects: 2051

Group type: EXPERIMENTAL
Intervention: Validation set (scoring model)
Number of subjects: 2051
Study: 33895720

Group type: EXPERIMENTAL
Intervention: Entry into differentiated service delivery (DSD) at 6 months after one suppressed viral load
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Entry into differentiated service delivery (DSD) at 6 months after two suppressed viral loads
Number of subjects: 90

Group type: COMPARATOR
Intervention: Current standard of care (entry into DSD at 12 months after two suppressed viral loads)
Number of subjects: 90
Study: 36322218

Group type: EXPERIMENTAL
Intervention: Couple-based HIV/STI intervention
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (couples without IPV)
Number of subjects: 230
Study: 33656475

Group type: EXPERIMENTAL
Intervention: SAAM intervention (1 session/week during 4 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 25
Study: 32943769

Group type: EXPERIMENTAL
Intervention: Isomaltulose (GI 32)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sucrose (GI 65)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sucralose (non-caloric negative control)
Number of subjects: 55
Study: 35831932

Group type: EXPERIMENTAL
Intervention: Prednisone and azathioprine (n=43)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (n=42)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Group A (immunosuppressive therapy)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Group B (untreated control cohort)
Number of subjects: 85
Study: 34196378

Group type: EXPERIMENTAL
Intervention: Nox-T3 automatic scoring algorithm
Number of subjects: 283
Study: 35115209

Group type: EXPERIMENTAL
Intervention: Elevated serum GDF-15 levels in patients with diabetes
Number of subjects: 3001

Group type: EXPERIMENTAL
Intervention: Addition of serum GDF-15 to conventional risk factors in patients with diabetes
Number of subjects: 3001

Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 3001
Study: 33766759

Group type: EXPERIMENTAL
Intervention: Soshiho-tang (SSHT) administered three times a day for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soshiho-tang (SSHT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 35060622

Group type: EXPERIMENTAL
Intervention: Standard fixed-effects model (FE)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Dynamic panel model using structural equation modeling (ML-SEM)
Number of subjects: 303
Study: 34473068

Group type: EXPERIMENTAL
Intervention: mHealth-enabled Integrated Care (IC) model
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 59
Study: 32998471

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus reuteri DSM 17938)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Prebiotic (agave inulin)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Synbiotic (Lactobacillus reuteri DSM 17938 plus agave inulin)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37